Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.25 USD
Change Today -0.31 / -4.73%
Volume 49.1K
KIN On Other Exchanges
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

kindred biosciences inc (KIN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/28/14 - $17.25
52 Week Low
12/4/14 - $5.98
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

kindred biosciences inc (KIN) Related Businessweek News

View More BusinessWeek News

kindred biosciences inc (KIN) Details

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidate is SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-010 for management of weight loss in cats; and KIND-012 for treatment of fevers in horses. It is also developing biologics products, such as KIND-510, a feline erythropoeitin for treatment of anemia in cats; KIND-502 for the treatment of allergic and immune-mediated diseases; KIND-506 for the treatment of inflammatory and autoimmune diseases; KIND-507 for the treatment of immune-mediated diseases; KIND-504, a cancer vaccine; and KIND-501, an antiangiogenic biologic for cancer in dogs. The company was founded in 2012 and is headquartered in Burlingame, California.

43 Employees
Last Reported Date: 03/13/15
Founded in 2012

kindred biosciences inc (KIN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $495.5K
Co-Founder, Chief Operating Officer and Secre...
Total Annual Compensation: $386.9K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $345.7K
Compensation as of Fiscal Year 2014.

kindred biosciences inc (KIN) Key Developments

Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from Russell 2000 Index

Kindred Biosciences, Inc. will be removed from Russell 2000 Index

Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from Russell 3000 Index

Kindred Biosciences, Inc. will be removed from the Russell 3000 Index.

Kindred Biosciences, Inc. Appoints Jennifer Elliott as Vice President of Legal Affairs and Intellectual Property

Kindred Biosciences, Inc. announced the appointment of Jennifer Elliott as Vice President of Legal Affairs and Intellectual Property. Dr. Elliott joins KindredBio from Genentech, where she most recently served as Associate General Counsel and Director of Patent Law.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KIN:US $6.25 USD -0.31

KIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aratana Therapeutics Inc $19.68 USD +0.66
View Industry Companies

Industry Analysis


Industry Average

Valuation KIN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KINDRED BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at